Kura Oncology/$KURA
1D1W1MYTD1Y5YMAX
About Kura Oncology
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.
- Ticker
- $KURA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 260
- Headquarters
- San Diego, United States
- Website
- kuraoncology.com
Kura Oncology Metrics
BasicAdvanced
$966M
-
-$3.36
0.38
-
Price and volume
Market cap
$966M
Beta
0.38
52-week high
$12.49
52-week low
$6.95
Average daily volume
1.4M
Financial strength
Current ratio
4.733
Quick ratio
4.502
Long term debt to equity
39.122
Total debt to equity
50.495
Interest coverage (TTM)
-224.01%
Profitability
EBITDA (TTM)
-316.799
Gross margin (TTM)
-236.72%
Net profit margin (TTM)
-384.30%
Operating margin (TTM)
-411.90%
Effective tax rate (TTM)
-0.03%
Revenue per employee (TTM)
$300,000
Management effectiveness
Return on assets (TTM)
-31.30%
Return on equity (TTM)
-167.71%
Valuation
Price to revenue (TTM)
12.416
Price to book
19.95
Price to tangible book (TTM)
19.95
Price to free cash flow (TTM)
-8.165
Free cash flow yield (TTM)
-12.25%
Free cash flow per share (TTM)
-1.33
Growth
Revenue change (TTM)
-7.27%
Earnings per share change (TTM)
48.78%
3-year earnings per share growth (CAGR)
17.92%
10-year earnings per share growth (CAGR)
7.41%
What the Analysts think about Kura Oncology
Analyst ratings (Buy, Hold, Sell) for Kura Oncology stock.
Kura Oncology Financial Performance
Revenues and expenses
Kura Oncology Earnings Performance
Company profitability
Kura Oncology News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.